Search

Displaying results 4171 - 4180 of 7186 in total
  1. Drug

    Diazepinomicin

    go.drugbank.com/drugs/DB12420
    Investigational

    Diazepinomicin is a natural product derived from a non-pathogenic micro-organism. … Discovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and

  2. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    prior to discharge from hospital and at home during their recovery period. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both

  3. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    T-cell engager to receive marketing approval. … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.

  4. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048). … Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells.

  5. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for

  6. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia.

  7. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Then, the medium is filtered and separated from the HUCBCs. … Thus, the media in which they are cultured is believed to also have therapeutic potential.

  8. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    It contains no preservatives. … It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency.

  9. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588]. … It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad

  10. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.